3-(3-(2-(dimethylamino)ethoxy)phenoxy)propylamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-(3-(2-(dimethylamino)ethoxy)phenoxy)propylamine
• 英文别名: 3-[3-[2-(dimethylamino)ethoxy]phenoxy]propan-1-amine
• 化学式: C₁₃H₂₂N₂O₂
• 分子量: 238.33
• InChiKey: ARUVTYFYWKOZBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  47.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(3-(2-(dimethylamino)ethoxy)phenoxy)propylamine 、 5-[(6-甲基-3-吡啶基)甲基]-2-(硝基氨基)-4(1H)-嘧啶酮 以 吡啶 为溶剂， 反应 24.0h， 以to give 2-[3-(3-(2-dimethylaminoethoxy)phenoxy)propylamino]-5-(6-methyl-3-pyridylmethyl)-4-pyrimidone的产率得到2-[3-(3-(2-dimethylaminoethoxy)phenoxy)propylamino]-5-(6-methyl-pyridin-3-ylmethyl)-4-pyrimidone
  参考文献：
  名称：

  Phenyl alkylaminopyrimidones

  摘要：

  这些化合物是苯基烷基氨基嘧啶酮，是组胺H.sub.2-拮抗剂。本发明的一个具体化合物是2-[2-[3-(二甲氨基甲基)苄基硫基]乙基氨基]-5-(6-甲基-3-吡啶基甲基)-4-嘧啶酮。

  公开号：

  US04496567A1

文献信息

• Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0013071A1

  公开（公告）日：1980-07-09

  The invention provides new histamine H2- antagonist compounds of Structure 1 in which R' is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen, trifluoromethyl, nitro, amino, lower alkylamino, lower alkanoylamino, di(lower alkyl)amino or cyano; R2 is in the 3-, 4- or 5- position and is hydrogen, or R2 is lower alkyl substituted by amino, lower alkylamino, di(lower alkyl)amino, N-piperidino or N-pyrollidino, or R2 is ethoxy or propoxy w-substituted by amino, lower alkylamino, di(lower alkyl)amino, N-piperidino or N-pyrollidino; Y is methylene or oxygen and X is methylene or sulphur provided that one or two of the groups X and Y is methylene; Z is hydrogen or lower alkyl; A is C1-C5 alkylene or-(CH2)pW-(CH2)q-where W is oxygen or sulphur and p and q are such that their sum is from 1 to4, and B is hydrogen, methyl, C3-C6 cycloalkyl, a heteroaryl group optionally substituted by one or more of the groups lower alkyl, lower alkoxy, halo, hydroxy and amino, or B is a naphthyl, 6-(2,3-dihydro-1,4-benzodioxinyl), a 4- or 5-(1,3-benzodioxolyl) group, or a phenyl group optionally substituted with one or more lower alkyl, lower alkoxy, halogen, aryl(lower alkoxy), hydroxy, lower alkoxy-lower alkoxy, trifluoromethyl, di(lower alkyl)amino, phenoxy, halophenoxy, lower alkoxyphenoxy, phenyl, halophenyl or lower alkoxyphenyl groups and pharmaceutical compositions containing them. A compound of Structure 1 can be prepared by reacting a compound of Structure 3 in which Q is nitroamino, loweralkylthio, benzylthio or halogen with an amine of Structure 2, in which R3 is in the 3-, 4- or 5p position and is hydrogen, lower alkyl substituted by a group R4, or is R4CH2CH2O-or R4CH2CH2CH2O-, where R' is di(lower alkyl)amino, N-piperidino, N-pyrrollidino, a protected amino group or a protected lower alkylamino group, and where necessary any amino-protecting group present in the substituent R3 is removed.

  本发明提供了结构 1 的新型组胺 H2- 拮抗剂化合物 其中R'是氢、低级烷基、低级烷氧基、羟基、卤素、三氟甲基、硝基、氨基、低级烷基氨基、低级烷酰氨基、二（低级烷基）氨基或氰基；R2 位于 3-、4-或 5-位且为氢，或 R2 为被氨基、低级烷基氨基、二（低级烷基）氨基、N-哌啶基或 N-吡咯烷基取代的低级烷基，或 R2 为被氨基、低级烷基氨基、二（低级烷基）氨基、N-哌啶基或 N-吡咯烷基取代的乙氧基或丙氧基；Y 为亚甲基或氧，X 为亚甲基或硫，条件是 X 和 Y 中的一个或两个基团为亚甲基；Z 为氢或低级烷基；A是C1-C5亚烷基或-(CH2)pW-( )q-其中W是氧或硫，p和q的和为1至4，B是氢、甲基、C3-C6环烷基、任选被一个或多个基团低级烷基、低级烷氧基、卤代、羟基和氨基取代的杂芳基，或者B是萘基、6-(2,3-二氢-1,4-苯并二噁烷基)、4-或5-(1、3-苯并二恶茂基）基团，或任选被一个或多个低级烷基、低级烷氧基、卤素、芳基（低级烷氧基）、羟基、低级烷氧基-低级烷氧基、三氟甲基、二（低级烷基）氨基、苯氧基、卤代苯氧基、低级烷氧基苯氧基、苯基、卤代苯基或低级烷氧基苯基基团取代的苯基基团以及含有它们的药物组合物。结构 1 的化合物可通过结构 3 的化合物（其中 Q 为硝基氨基、低级烷硫基、苄硫基或卤素） 与结构 2 的胺反应制备，其中 R3 位于 3-、4-或 5p 位，是氢、被基团 R4 取代的低级烷基或 R4 O- 或 R4 O-，其中 R' 是二（低级烷基）氨基、N-哌啶基、N-吡咯烷基、受保护的氨基或受保护的低级烷基氨基，必要时去除取代基 R3 中存在的任何氨基保护基。
• US4496567A
  申请人：——

  公开号：US4496567A

  公开（公告）日：1985-01-29
• [EN] NEW HISTAMINE H2-ANTAGONISTS
  申请人：——

  公开号：WO1980000966A1

  公开（公告）日：1980-05-15

  (EN) New histamine H2-antagonist compounds of structure 1 (FORMULA) in which R1 is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen trifluoromethyl, nitro, amino, lower alkylamino, lower alkanoylamino, di (lower alkyl) amino or cyano; R2 is in the 3-, 4- or 5-position and is hydrogen, R2 is lower alkyl substituted by amino, lower alkylamino, di (lower alkyl) amino, N-piperidino or N-pyrollidino, or R2 is ethoxy or propoxy (Alpha)-substituted by amino, lower alkylamino, di (lower alkyl) amino, N-piperidino or N-pyrollidino; Y is methylene or oxygen and X is methylene or sulphur provided that one or two of the groups X and Y is methylene; Z is hydrogen or lower alkyl; A is C1-C5 alkylene or -(CH2)pW-(CH2)q where W is oxygen or sulphur and p and q are such that their sum is from 1 to 4, and B is hydrogen methyl, C3-C6 cycloalkyl, a heteroaryl group optionally substituted by one or more of the groups lower alkyl, lower alkoxy, halo, hydroxy and amino, or B is naphthyl, 6-(2,3-dihydro-1,4-benzodioxinyl), a4- or 5-(1,3-benzodioxolyl) group, or a phenyl group optionally substituted with one or more lower alkyl, lower alkoxy, halogen, aryl (lower alkoxy), hydroxy, lower alkoxy-lower alkoxy, trifluoromethyl, di (lower alkyl) amino, phenoxy, halophenoxy, lower alkoxyphenoxy, phenyl, halophenyl or lower alkoxyphenyl groups and pharmaceutical compositions containing them. A compound of structure 1 can be prepared by reacting a compound of structure 3 in which Q is nitroamino, loweralkylthio, benzylthio or halogen with an amine of structure 2, in which (FORMULA) R3 is in the 3-, 4- or 5-position and is hydrogen, lower alkyl substituted by a group R4, or is R4CH2CH2O-or R4CH2CH2CH2O-, where R4 is di(lower alkyl)amino, N-piperidino, N-pyrrollidino, a protected amino group or a protected lower alkylamino group, and where necessary any amino-protecting group present in the substituent R3 is removed. (FR) Nouveaux composes antagonistes des recepteurs-H2 de l"histamine, de structure 1 (FORMULE) dans laquelle R1 represente l"hydrogene, un groupe alkyle inferieur, alkoxy inferieur, hydroxy, halogene, trifluoromethyle, nitro, amino, alkylamino inferieur alcanoylamino inferieur, di(alkyle inferieur) aminoe ou cyano; R2 se trouve en position 3-, 4-, ou 5- et represente l"hydrogene ou R2 represente un groupe alkyle inferieur substitue par amino, alkylamino inferieur, di(alkyle inferieur) amino, N-piperidino ou N-pyrrolidino, ou R2 represente un groupe ethoxy ou propoxy (Alpha)-substitue par amino, alkylamino inferieur, di(alkyle inferieur) amino, N-piperidino ou N-pyrrolidino; Y represente un groupe methylene ou l"oxygene et X represente un methylene; Z represente l"hydrogene ou un groupe alkyle inferieur; A represente un groupe alkylene en C1-C5 ou -(CH2)pW-(CH2)q dans lequel W represente l"oxygene ou le soufre et p et q sont tels que leur somme est de 1 a 4, et B represente l"hydrogene, un groupe methyle, cycloalkyle en C3-C6, un groupe heteroaryle facultativement substitue par un ou plus des groupes alkyle inferieurs, alkoxy inferieurs, halo, hydroxy et amino ou B represente un groupe naphtyle, 6-(2,3-dihydro-1,4-benzodioxinyl), un groupe 4- ou 5-(1,3-benzodioxolyl) ou un groupe phenyle facultativement substitue par un ou plus d"un groupe alkyle inferieur, alkoxy inferieur, halogene, aryl (alkoxy inferieur), hydroxy, alkoxy inferieur-alkoxy inferieur, trifluoromethyl, di(alkyle inferieur) amino, phenoxy, halophenoxy, alkoxy inferieur phenoxy, phenyle, alophenyl ou groupes alkoxy inferieur phenyle et les compositions pharmaceutiques les contenant. Un compose de structure 1 peut etre prepare en faisant reagir un compose de structure 3 dans laquelle Q represente un groupe nitroamino, thio-alkyle inferieur, benzylthio ou un halogene avec une amine de structure 2 dans laquelle (FORMULE) R3 est en position 3-, 4- ou 5- et represente l"hydrogene, un groupe alkyl inferieur substitue par un groupe R4 ou represente un groupe R4CH2CH2O- ou R4CH2CH2CH2O- dans lequel R4 represente un groupe di(alkyle inferieur) amino, N-piperidino, N-pyrrolidino, un groupe amino protege ou un groupe akylamino inferieur protege et si necessaire, tout groupe protecteur de groupe amine present dans le substituent R3 est elimine.